证券代码：300110 证券简称：华仁药业 公告编号：2025-071 华仁药业股份有限公司 关于持股 5%以上股东减持计划预披露的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载，误导性陈述或重大遗漏。 华仁药业股份有限公司（以下简称"华仁药业"或"公司"）于近日收到持股5% 以上股东华仁世纪集团有限公司（以下简称"华仁世纪集团"）《关于减持华仁药 业股份计划的告知函》，华仁世纪集团计划自减持计划公告之日起十五个交易日 后的三个月内通过集中竞价交易方式、大宗交易方式减持不超过公司总股本3% 的股份，即不超过35,466,300股，其中通过集中竞价交易方式减持不超过公司总 股本1%的股份，即不超过11,822,100股，通过大宗交易方式减持股数不超过公司 总股本2%的股份，即不超过23,644,200股。现将具体情况公告如下： 一、减持主体的基本情况 1、减持主体的名称：华仁世纪集团有限公司。 2、减持主体持有股份的总数量、占公司总股本的比例：截至本公告披露日， 华仁世纪集团持有公司股份 81,543,026 股，占公司总股本的 6.90%。 二、本次减持计划的主要内容 1、拟减 ...

Core Insights - Huarun Pharmaceutical (300110.SZ) reported a total revenue of 976 million yuan for Q3 2025, ranking 59th among disclosed peers, which represents a decrease of 97.35 million yuan or 9.07% year-on-year [1] - The net profit attributable to shareholders was 54.58 million yuan, ranking 72nd among peers, down by 40.95 million yuan or 42.87% compared to the same period last year [1] - The net cash inflow from operating activities was 257 million yuan, ranking 38th among peers, a decrease of 28.76 million yuan or 10.08% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 58.02%, ranking 108th among peers, a decrease of 0.72 percentage points from the previous quarter, but an increase of 16.25 percentage points year-on-year [3] - The latest gross profit margin is 34.15%, ranking 86th among peers, down by 3.59 percentage points from the previous quarter and down by 1.95 percentage points year-on-year [3] - The latest return on equity (ROE) is 4.03%, ranking 65th among peers, an increase of 0.57 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is 0.05 yuan, ranking 84th among peers, a decrease of 0.03 yuan or 42.82% year-on-year [3] - The latest total asset turnover ratio is 0.29 times, ranking 64th among peers, an increase of 0.07 times or 33.75% year-on-year [3] - The latest inventory turnover ratio is 2.25 times, ranking 36th among peers, an increase of 0.13 times or 5.94% year-on-year [3] Shareholder Information - The number of shareholders is 40,600, with the top ten shareholders holding a total of 501 million shares, accounting for 42.34% of the total share capital [3] - The largest shareholder is Xi'an Qujiang Tianshou Health Investment Partnership (Limited Partnership) with a holding of 20.01% [3]

Core Insights - The company reported a positive recovery in its operations for Q3 2025, achieving a revenue of 352 million yuan, representing a year-on-year growth of 16.62% [1] Group 1: Business Performance - The company has focused on building product strength, particularly in core product lines such as nephrology, respiratory, and large-volume preparations, which has laid a solid foundation for revenue growth [1] - Cumulative R&D investment reached 48.37 million yuan in the first three quarters of 2025, with significant improvements in R&D conversion efficiency [1] - The company obtained eight new approvals for raw materials and formulations, enhancing its product matrix in key therapeutic areas [1] Group 2: Innovation and Product Development - The company has entered special approval procedures for its innovative medical device, a hardness measuring instrument, which will accelerate the development and market entry of high-end male medical devices [1] - As of the end of Q3 2025, the company and its subsidiaries held a total of 560 authorized patents, including 105 invention patents, which strengthens product competitiveness and supports industry chain extension [2] Group 3: Market Strategy - The company has successfully executed multiple procurement projects, including the 10th batch of national drug procurement and various provincial procurements, which will enhance market penetration [2] - The company is actively participating in the "three advances" initiative for procurement products, aiming to expand market reach in various provinces [2] - Future strategies include reinforcing product strength through a full industry chain layout and improving operational efficiency to solidify industry position and drive steady revenue growth [2]

Core Insights - Huaren Pharmaceutical reported a revenue of 352,374,010.10 yuan for Q3 2025, representing a year-on-year increase of 16.62% [2] - The net profit attributable to shareholders of the listed company was 17,246,910.68 yuan, showing a year-on-year decline of 22.72% [2] Financial Performance - Revenue for Q3 2025: 352.37 million yuan, up 16.62% year-on-year [2] - Net profit for Q3 2025: 17.25 million yuan, down 22.72% year-on-year [2]

Company Performance - Huarun Pharmaceutical reported a revenue of approximately 976 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 9.07% [1] - The net profit attributable to shareholders was approximately 54.58 million yuan, down 42.87% year-on-year [1] - Basic earnings per share were 0.0462 yuan, reflecting a decrease of 42.82% compared to the previous year [1] Market Context - As of the report, Huarun Pharmaceutical has a market capitalization of 3.9 billion yuan [2] - The A-share market has recently surpassed 4000 points, indicating a significant market resurgence after a decade of stagnation, with technology leading the market's new "slow bull" pattern [2]

证券代码：300110 证券简称：华仁药业 公告编号：2025-069 二、董事会会议审议情况 全体与会董事经认真审议和表决，形成以下决议： （一）审议通过《2025 年第三季度报告》 经审议，全体董事认为公司编制《2025 年第三季度报告》的程序符合有关法 律法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 2025 年第 三季度的财务状况和经营情况，不存在任何虚假记载、误导性陈述或重大遗漏。 公司《2025 年第三季度报告》的具体内容详见公司同日披露在中国证监会指 定创业板信息披露网站巨潮资讯网的相关公告（公告编号：2025-070）。 本议案已经公司董事会审计委员会审议通过。 华仁药业股份有限公司 第八届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 一、董事会会议召开情况 华仁药业股份有限公司（以下简称"公司"）第八届董事会第十二次会议于 2025 年 10 月 29 日以现场和网络会议相结合的形式召开。会议通知已于 2025 年 10 月 17 日以电子邮件方式发给各位董事。会议由代行董事长侯瑞鹏先生召集并 主 ...

Revenue and Profitability - Revenue for Q3 2025 reached ¥352,374,010.10, an increase of 16.62% compared to the same period last year[2] - Net profit attributable to shareholders decreased by 22.72% to ¥17,246,910.68 in Q3 2025, and by 42.87% to ¥54,579,793.85 for the year-to-date[2] - Basic earnings per share for Q3 2025 were ¥0.0146, down 22.75% year-on-year[2] - Total operating revenue for the current period is RMB 976,270,444.55, a decrease of 9.07% compared to RMB 1,073,621,963.53 in the previous period[21] - Net profit for the period was ¥57,398,016.43, down from ¥100,471,124.16, representing a decline of about 43%[23] - Basic and diluted earnings per share decreased to ¥0.0462 from ¥0.0808, a drop of approximately 42.5%[23] Assets and Liabilities - Total assets as of September 30, 2025, were ¥3,396,808,707.61, a decrease of 0.91% from the end of the previous year[2] - Total assets decreased to RMB 3,396,808,707.61 from RMB 3,428,120,079.39, a decline of 0.9%[19] - Total liabilities decreased to RMB 1,970,961,247.11 from RMB 2,054,191,740.04, a reduction of 4.0%[19] - Non-current assets decreased slightly to RMB 2,234,426,391.53 from RMB 2,243,141,469.80, a decline of 0.3%[18] - The total equity attributable to the parent company increased to RMB 1,355,366,082.86 from RMB 1,300,786,289.01, a growth of 4.2%[19] Cash Flow and Financial Activities - Cash flow from operating activities for the year-to-date was ¥256,623,163.38, down 10.08% compared to the same period last year[2] - Cash flow from operating activities generated ¥256,623,163.38, compared to ¥285,386,815.04 in the previous period, a decrease of about 10%[25] - Cash and cash equivalents increased to RMB 222,890,633.82 from RMB 163,813,254.90, representing a growth of 36%[18] - Cash and cash equivalents at the end of the period increased to ¥186,178,965.82 from ¥119,922,385.96, reflecting a net increase of approximately 55.4%[26] - The net cash flow from financing activities for the year-to-date was -¥175,892,477.20, a decrease of 51.18% compared to the previous year[10] - Financing activities produced a net cash outflow of ¥175,892,477.20, an improvement from an outflow of ¥360,267,179.13 in the previous period[25] Inventory and Prepayments - Inventory decreased by 20.64% to ¥252,561,995.35, attributed to improved inventory management[6] - Inventory decreased significantly to RMB 252,561,995.35 from RMB 318,237,397.12, a reduction of 20.6%[18] - The company reported a significant increase in prepayments by 63.04% to ¥33,075,466.47, mainly due to increased operational prepayments[6] Financial Performance Metrics - Financial expenses decreased by 21.95% to ¥33,783,971.27 for the year-to-date, primarily due to reduced interest expenses from loan scale compression[8] - The weighted average return on equity for Q3 2025 was 1.28%, an increase of 0.47% from the previous year[2] - Tax expenses decreased to ¥5,879,952.99 from ¥13,939,611.92, a reduction of approximately 57.8%[22] - Other income increased to ¥2,180,154.49 from ¥582,194.48, marking a significant rise of about 274%[22] - The company reported a credit impairment loss of ¥-13,968,652.22, worsening from ¥-913,335.01 in the previous period[22]

Group 1 - The core point of the article is that Huaren Pharmaceutical has received approval from the National Medical Products Administration for its product "Nafamostat Mesilate Injection" [1] - Huaren Pharmaceutical's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 95.79% and the pharmaceutical commerce accounts for 4.21% [1] - As of the report date, Huaren Pharmaceutical has a market capitalization of 4 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated 80 billion USD in overseas licensing this year [1] - It highlights a conversation with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine while the primary market faces fundraising challenges [1]

关于全资子公司盐酸奈福泮注射液取得 药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司安徽恒星制药 有限公司（以下简称"安徽恒星制药"）收到国家药品监督管理局核准签发的"盐 酸奈福泮注射液"的《药品注册证书》，具体情况公告如下： 证券代码：300110 证券简称：华仁药业 公告编号：2025-068 华仁药业股份有限公司 一、药品基本情况 1．药品名称 药品通用名称：盐酸奈福泮注射液 英文名/拉丁名：Nefopam Hydrochloride Injection 2．剂型：注射剂 3．申请事项：药品注册（境内生产） 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注 册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产 工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销 售。 名称：安徽恒星制药有限公司 地址：合肥市包河工业区纬五路 15 号 13．药品批准文号：国药准字 H20255748 14．药品批准文号有效期：至 2030 年 ...

Group 1 - The core viewpoint of the news is that Huaren Pharmaceutical's stock performance and financing activities indicate a stable but cautious market position, with significant changes in revenue and profit margins reported in recent financial results [1][2]. Group 2 - As of October 23, Huaren Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 60.76 million yuan. The financing buy-in amount was 9.08 million yuan, while the financing repayment was 11.02 million yuan, resulting in a net financing buy-in of -1.94 million yuan [1]. - The total balance of margin trading for Huaren Pharmaceutical reached 256 million yuan, accounting for 6.35% of its market capitalization, which is above the 60th percentile level over the past year, indicating a relatively high financing level [1]. - The company has not engaged in any short selling activities on October 23, with no shares sold or repaid, and the short selling balance also stood at zero [1]. - Huaren Pharmaceutical's main business revenue composition includes: basic infusion (40.63%), peritoneal dialysis fluid (34.90%), therapeutic preparations (14.92%), medical devices (8.14%), and others (1.41%) [1]. Group 3 - As of October 10, the number of shareholders for Huaren Pharmaceutical was 40,700, an increase of 0.49% from the previous period, while the average circulating shares per person decreased by 0.49% to 29,013 shares [2]. - For the first half of 2025, Huaren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2]. Group 4 - Since its A-share listing, Huaren Pharmaceutical has distributed a total of 294 million yuan in dividends, with cumulative distributions of 49.65 million yuan over the past three years [3].